glp-1 drugs and autoimmune disease Lower Risk of Death by 44% in Obesity Glucagon-like peptide and its receptor
Description
While GEP-44 remains in preclinical development, these early findings place SureNano Science within a strategically important segment of the obesity treatment landscape
doi: 10.3389/fendo.2024.1309118
Many patients benefit from drinking 80100 ounces of water daily while taking GLP-1 medications
Therefore, gastroparesis may be a marker of increased morbidity [49]
To address the limitations of GLP-1 analogs, ongoing preclinical and clinical studies are evaluating the combined use of MSTN inhibitors and GLP-1 agonists
Lifestyle modification and weight loss are recommended as the foundation for disease management [9]
